Company Profile For Lupin Limited
Lupin Limited (LUPN.BO) (Bombay Stock Exchange)
sector: Healthcare ·
industry: Pharmaceuticals - Generic & Specialty ·
Overview
Lupin Limited is an Indian-based pharmaceutical company. The Company develops and markets a range of generic formulations and Active Pharmaceutical Ingredients (APIs) in markets around the world. In April 2008, the Company launched suprax 400 milligram tablets (Cefixime USP) in the United States. In July 2008, the Company acquired Hormosan Pharma GmbH. In September 2008, the Company acquired a majority stake in Pharma Dynamics (PD) in South Africa. In March 2009, Lupin Limited announced the completion of acquisition of a majority stake in Multicare Pharmaceuticals Philippines, Inc.
Quick Financial Synopsis
BRIEF: For the six months ended 30 September 2009, Lupin Limited's revenues increased 25% to RS22.75B. Net income increased 32% to RS3B. Revenues reflects increased revenue within India and higher revenue from outside India. Net income also reflects a decrease in interest and finance charges. Lupin Limited develops and markets a wide range of quality, affordable generic and branded formulations and APIs in multiple markets across the world.
Company Address
Lupin Limited
159 CST Road
Kalina
Santacruz (E)
Mumbai 400 098
P: +9122.66402222
F: +9122.66402130
159 CST Road
Kalina
Santacruz (E)
Mumbai 400 098
P: +9122.66402222
F: +9122.66402130
Total Employees
6000
Find Out More About LUPN.BO
Market Update
India
US
UK- Asia
- Most Actives
Commodities
| Commodity | Last | Pct Chg | Trade Date/Time |
|---|---|---|---|
| Oil | 76.58 | -1.15% | 11/25 01:42 IST |
| Gold | 1168.6 | +0.33% | 11/25 01:22 IST |
